0 CHECKOUT

Keloids - Pipeline Review, H2 2015

  • ID: 3440666
  • September 2015
  • 49 pages
  • Global Markets Direct
1 of 4

Keloids - Pipeline Review, H2 2015

Summary

The report ‘Keloids - Pipeline Review, H2 2015’, provides an overview of the Keloids’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Keloids Overview

Therapeutics Development

Pipeline Products for Keloids - Overview

Pipeline Products for Keloids - Comparative Analysis

Keloids - Therapeutics under Development by Companies

Keloids - Therapeutics under Investigation by Universities/Institutes

Keloids - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Keloids - Products under Development by Companies

Keloids - Products under Investigation by Universities/Institutes

Keloids - Companies Involved in Therapeutics Development

RXi Pharmaceuticals Corporation

Vida Therapeutics Inc.

Keloids - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

CIGB-128 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CM-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

koebnerisin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

psoriasin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RXI-109 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

V-2248 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VTI-3000 Series - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Keloids - Recent Pipeline Updates

Keloids - Dormant Projects

Keloids - Discontinued Products

Keloids - Product Development Milestones

Featured News & Press Releases

Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology

Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study

Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders

Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period

Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision

Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109

Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Keloids, H2 2015

Number of Products under Development for Keloids - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Keloids - Pipeline by RXi Pharmaceuticals Corporation, H2 2015

Keloids - Pipeline by Vida Therapeutics Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Keloids Therapeutics - Recent Pipeline Updates, H2 2015

Keloids - Dormant Projects, H2 2015

Keloids - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Keloids, H2 2015

Number of Products under Development for Keloids - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

RXi Pharmaceuticals Corporation
Vida Therapeutics Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.